Sabatini Brent 4
4 · Vir Biotechnology, Inc. · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
Vir Biotechnology (VIR) SVP Brent Sabatini Sells 1,530 Shares
What Happened Brent Sabatini, SVP and Chief Accounting Officer of Vir Biotechnology, sold 1,530 shares of VIR on Feb 13, 2026 at $7.79 per share, generating proceeds of $11,919. The filing notes this was an automatic, mandatory sale under a Rule 10b5-1 arrangement to cover tax withholding related to vested restricted stock units — not a discretionary trade.
Key Details
- Transaction date and price: Feb 13, 2026 — 1,530 shares sold at $7.79 each (total $11,919).
- Transaction type: Sale (S); described as open market or private sale in the filing.
- Footnote F1: Sale was automatic/mandatory under a Rule 10b5-1 plan to satisfy tax withholding on RSU vesting — not a voluntary trade.
- Footnote F2: Reporting person’s holdings include prior purchases of 2,290 and 485 shares acquired via the employee stock purchase plan on May 30, 2025 and Nov 28, 2025, respectively.
- Shares owned after transaction: Not specified in the provided excerpt of the filing.
- Filing date/timeliness: Form 4 filed Feb 18, 2026. Given the Feb 13 transaction and the Feb 16 Presidents Day holiday, this filing is within the standard two-business-day window.
Context This sale was executed to satisfy tax withholding obligations tied to RSU vesting and is labeled as automatic under a 10b5-1 plan, which generally means it should not be interpreted as a directional signal about the officer’s view of the company. For retail investors, purchases typically carry more informational weight than routine withholding sales like this one.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-02-13$7.79/sh−1,530$11,919→ 47,872 total
Footnotes (2)
- [F1]Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person.
- [F2]Includes 2,290 and 485 shares of common stock acquired by the Reporting Person on May 30, 2025 and November 28, 2025, respectively, pursuant to an employee stock purchase program.